Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EPS (Weighted Average and Diluted): 2017-2025

Historic EPS (Weighted Average and Diluted) for Ultragenyx Pharmaceutical (RARE) over the last 5 years, with Sep 2025 value amounting to -$1.81.

  • Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) fell 29.29% to -$1.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.93, marking a year-over-year increase of 7.20%. This contributed to the annual value of -$6.29 for FY2024, which is 23.76% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported EPS (Weighted Average and Diluted) of -$1.81 as of Q3 2025, which was down 54.70% from -$1.17 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year EPS (Weighted Average and Diluted) high stood at -$1.08 for Q3 2021, and its period low was -$3.50 during Q3 2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$1.57 (2025), whereas its average is -$1.74.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) slumped by 287.58% in 2021, and later surged by 37.22% in 2024.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) stood at -$1.79 in 2021, then decreased by 20.67% to -$2.16 in 2022, then spiked by 33.33% to -$1.44 in 2023, then grew by 4.17% to -$1.38 in 2024, then decreased by 29.29% to -$1.81 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$1.81 for Q3 2025, versus -$1.17 for Q2 2025 and -$1.57 for Q1 2025.